StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 8.8
Power Rank trend -> Rising
02/12/2025 16:23:00 EST
Ginkgo Bioworks Holdings (DNA)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, DNA has been trading in a range between $14.29 and $8.56 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
DNA is trading below resistance at $14.29, about 16% to the upside. There is support at $9.31 -24% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Ginkgo Bioworks Holdings $DNA entered a Green zone 55 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $8.2, a potential down side of -42.46% from the recent price of 14.25. The stock is trading 351.93% (potential upside) below its 52 week high of $64.40 and 170.91 % (potential downside) above its 52 week low of $5.26 - based on the recent price.
Company Summary
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum.
News
| Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength? Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Source: Zacks Investment Research Thu, 06 Feb 2025 09:25:24 -0500 Sentiment: Positive |
| Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquarters. Source: PRNewsWire Thu, 06 Feb 2025 08:01:00 -0500 Sentiment: Neutral |
| Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). Source: Zacks Investment Research Wed, 29 Jan 2025 13:01:17 -0500 Sentiment: Positive |
| Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC) Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously, enabling GLBRC scientists to more efficiently discover and optimize synthesis of biofuels and bioproducts from plant biomass. Source: PRNewsWire Thu, 23 Jan 2025 08:01:00 -0500 Sentiment: Neutral |
| SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development LEXINGTON, Mass. & FREMONT, Calif.--(BUSINESS WIRE)--SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular spectroscopy for AI-driven discovery, and Ginkgo Bioworks. This partnership, fully funded by the Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, aims to accelerate the discovery and development of next-gen. Source: Business Wire Tue, 21 Jan 2025 07:00:00 -0500 Sentiment: Neutral |
Technicals 52 Week Hi: 64.4 52 Week Low: 5.26 Beta: 1.098 50 Day MA: 10.9908 200 Day MA: 13.3829 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.606 Forward PE: 0 Trailing PE: 0